drugset / Trial / NCT06620393
Effects of Dexmedetomidine on Agitation in Critically Ill TBI Patients
Phase 2/3
Not yet recruiting
72 enrolled
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Canadian Critical Care Trials Group · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Agitation is a frequent complication following traumatic braing injury in patients admitted to the intensive care unit. This agitation frequently results in the liberal use of rescue drugs such as antipsychotics, sedatives and opiates, which in turn may delay rehabilitation, liberation from mechanical ventilation and emergence from posttraumatic amnesia. Dexmedetomidine may be a better agent given it's light sedative properties. The main objective is to assess the feasibility of conducting a multicenter randomized controlled trial of dexmedetomidine following TBI in the ICU.
Timeline
- Start
- 2024-10-01
- Primary completion
- 2026-06-01
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexmedetomidine | Other / unclassified | 1.4 ug/kg | — |